Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
| Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
|---|---|---|---|---|
| Han Q et al. | 2018 | - | magnetic field, 50/60 Hz, co-exposure | - |
| Amiri M et al. | 2018 | intact cell/cell culture, human glioblastoma cell line (U-87) | 50/60 Hz, static magnetic field, magnetic field, co-exposure, also other exposures without EMF | - |
| Sanie-Jahromi F et al. | 2018 | - | 50/60 Hz, magnetic field, co-exposure | - |
| Consales C et al. | 2019 | - | magnetic field, 50/60 Hz | - |
| Oladnabi M et al. | 2019 | - | magnetic field, signals/pulses, 50/60 Hz | - |
| Yuan LQ et al. | 2020 | intact cell/cell culture, human nephroblastoma cell line G401, human embryonic renal epithelial cell line HEK293, human lung cancer cell line A549, human bronchial epithelial cell line BEAS-2B, human gastric cancer cell line SGC-7901, human gastric epithelial cell line GES-1, human pancreatic cancer cell line PANC-1, human pancreatic ductal epithelial cell line HPDE6-C7, wild-type (WT) mouse embryonic fibroblast (MEF) cells, NBS1-/-MEF and MDC1-/-MEF cells | static magnetic field, magnetic field, 50/60 Hz, co-exposure | - |
| Xu A et al. | 2020 | - | magnetic field, 50/60 Hz, low frequency | - |
| Masoudi-Khoram N et al. | 2022 | intact cell/cell culture, MCF-7 and MDA-MB-231 (human breast cancer cell lines) | magnetic field, low frequency, 50/60 Hz | - |
| Li Y et al. | 2019 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz, also other exposures without EMF | - |
| Aparicio-Bautista DI et al. | 2022 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz, low frequency | - |
| Choi JH et al. | 2022 | intact cell/cell culture, human hair bulb spheroid and hair follicle cultures | magnetic field, 50/60 Hz | - |
| Ambalayam S et al. | 2022 | animal, rat/Wistar | magnetic field, 50/60 Hz, low frequency | - |
| Alipour M et al. | 2022 | intact cell/cell culture, rat bone marrow-derived mesenchymal cells (BMSCs) | static magnetic field, magnetic field, 50/60 Hz, co-exposure | - |
| Lazzarini R et al. | 2023 | intact cell/cell culture, MDA-MB-231 cells (breast cancer cell line) and MDA-MB-231 (human breast cell line) | magnetic field, 50/60 Hz | - |
| Mercado-Sáenz S et al. | 2023 | intact cell/cell culture, yeast (<i>Saccharomyces cerevisiae</i>)/WS8105-1C | magnetic field, signals/pulses, 50/60 Hz, co-exposure, also other exposures without EMF | - |
| Ramazi S et al. | 2023 | intact cell/cell culture, MCF-7 (human breast cancer cell line) and HFF cells (human foreskin fibroblast cells) | magnetic field, 50/60 Hz, also other exposures without EMF, co-exposure | - |
| Jung JH et al. | 2017 | intact cell/cell culture, human mesenchymal stem cells | magnetic field, low frequency, 50/60 Hz | - |
| Kayhan H et al. | 2020 | intact cell/cell culture, human, neonatal, healthy primary dermal fibroblast and MCF7 cells (human metastatic breast cancer cells) | magnetic field, 50/60 Hz, low frequency | - |
| Reipert BM et al. | 1997 | intact cell/cell culture, FDCP-mix(A4) cell line (mouse bone marrow cells) | magnetic field, static magnetic field, 50/60 Hz, shielding/field deprivation | 0.2 µT–2 mT |
| Ismael SJ et al. | 1998 | animal, mouse/Swiss, whole body | magnetic field, static magnetic field, 50/60 Hz, DC | 0.4–20 µT |
| Kurian MV et al. | 2012 | intact cell/cell culture, H9c2 cells (myoblast from embryonal rat myocard) | magnetic field, 50/60 Hz, co-exposure | 1–240 µT |
| Kim HS et al. | 2014 | animal, mouse/BALB/c, whole body | magnetic field, 50/60 Hz | 2–200 µT |
| Rajendra P et al. | 2012 | intact cell/cell culture, sheep primary lymphocytes | 50/60 Hz, magnetic field | 5–100 µT |
| Maes A et al. | 2015 | intact cell/cell culture, C3A cells (clonal derivative of Hep G2, a human liver carcinoma cell line) | magnetic field, 50/60 Hz | 5–500 µT |
| Lai H et al. | 2004 | animal, rat/Sprague-Dawley, whole body | magnetic field, 50/60 Hz, co-exposure | 10–500 µT |
| Duong CN et al. | 2016 | intact cell/cell culture, HMO6 cells (human microglial cell line) | magnetic field, low frequency, 50/60 Hz, co-exposure | 0.01–1 mT |
| Brisdelli F et al. | 2014 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz, co-exposure | 0.01–2 mT |
| Hosseinabadi MB et al. | 2019 | human | magnetic field, low frequency, 50/60 Hz, occupational | 11.3–18.9 µT |
| Kim YW et al. | 2009 | animal, mouse/BALB/c, whole body | magnetic field, 50/60 Hz | 14–200 µT |
| Li Y et al. | 2014 | animal, zebrafish embryos (<i>Danio rerio</i>), whole body | magnetic field, 50/60 Hz | 30–800 µT |
| Verheyen GR et al. | 2003 | intact cell/cell culture, human lymphocytes | magnetic field, 50/60 Hz, co-exposure | 80–800 µT |
| Phillips JL | 1986 | intact cell/cell culture, human colon carcinoma cell line (Colo 205) | electric field, magnetic field, 50/60 Hz | 0.1 mT |
| Kumlin T et al. | 2002 | animal, mouse/BALB/CŒDBA/2, whole body | magnetic field, 50/60 Hz, co-exposure | 100 µT |
| Zuo H et al. | 2020 | intact cell/cell culture, PC12 (rat pheochromocytoma cells) | magnetic field, 50/60 Hz | 100 µT |
| Markkanen A et al. | 2008 | intact cell/cell culture, L929 cells (murine fibroblast cells) | magnetic field, 50/60 Hz, co-exposure | 100–300 µT |
| Saha S et al. | 2014 | animal, mouse/C57BL/6, whole body: <i>in utero</i> | magnetic field, 50/60 Hz, also other exposures without EMF | 100–300 µT |
| Lee JS et al. | 2004 | animal, mouse/BALB/c, whole body | magnetic field, 50/60 Hz | 0.1–0.5 mT |
| Akdag MZ et al. | 2010 | animal, rat/Sprague-Dawley, whole body | magnetic field, low frequency, 50/60 Hz | 100–500 µT |
| Akdag MZ et al. | 2013 | animal, rat/Sprague-Dawley, whole body | magnetic field, 50/60 Hz | 100–500 µT |
| Panagopoulos DJ et al. | 2013 | invertebrate, <i>Drosophila melanogaster</i>/Oregon-R, whole body | magnetic field, 50/60 Hz | 0.1–2.1 mT |
| Khadir R et al. | 1999 | intact cell/cell culture, neutrophils (from human venous blood) | magnetic field, 50/60 Hz, co-exposure | 0.1–44 mT |
| Robison JG et al. | 2002 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells), HL-60R (human acute myeloid leukaemia cells with retinoic acid receptor-alhpa gene mutation) and Raji cells (human Burkitt lymphoma cells) | magnetic field, 50/60 Hz | 150 µT |
| Watson JM et al. | 1998 | intact cell/cell culture, human endometrial stromal fibroblasts (primary cells and ESF-I (N5) cell line) and 12 endometrial, ovarian, and prostate cancer cell lines and immortazized human ovarian epithelial cells (OV-I) | magnetic field, 50/60 Hz, co-exposure | 200 µT |
| Park S et al. | 2015 | animal, rat/Sprague Dawley, whole body | magnetic field, 50/60 Hz | 200 µT |
| Sun W et al. | 2010 | intact cell/cell culture, isolated villi tissue | magnetic field, low frequency, 50/60 Hz | 0.2–0.4 mT |
| Grassi C et al. | 2004 | intact cell/cell culture, human neuroblastoma cell line (IMR 32) and rat pituitary (GH3) cell line | magnetic field, low frequency, 50/60 Hz, co-exposure | 200–500 µT |
| Feng B et al. | 2016 | intact cell/cell culture, human amniotic cells | magnetic field, 50/60 Hz | 0.2–2 mT |
| Koh EK et al. | 2008 | intact cell/cell culture, different human prostate carcinoma cell lines (DU145, LNCaP, PC3) | magnetic field, 50/60 Hz, power transmission line | 0.2–2.5 mT |
| Blumenthal NC et al. | 1997 | intact cell/cell culture, rat tendon fibroblasts and rat bone marrow osteoprogenitor cells (Sprague-Dawley rat) | magnetic field, static magnetic field, intermediate frequency, 50/60 Hz | 0.25–0.5 mT |
| Tofani S et al. | 2001 | intact cell/cell culture, WiDr (colon adenocarcinoma cells), MCF-7 (breast adenocarcinoma cells), MRC-5 (embryonal lung cells), animal, mouse/CD-1 nu-nu (nude), whole body | magnetic field, static magnetic field, low frequency, 50/60 Hz, DC | 300 µT–2.5 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.
